Adderall vs Ritalin: Which Is Harder on the Heart?

Creator: Ryan S. Sultan, MD
Published: 2026-11-12

By Ryan S. Sultan, MD
Psychiatrist · Columbia University Irving Medical Center
Published November 12, 2026 · 6-minute read

The evidence doesn't establish that amphetamines (Adderall, Vyvanse) or methylphenidate (Ritalin, Concerta) is the safer class for the heart. In adult trials, systolic blood pressure rose by 1.66 mm Hg with methylphenidate and 2.3 mm Hg with amphetamines compared with placebo, and confidence in both estimates was rated very low.¹

No study reviewed here shows that either class is associated with more heart attacks, strokes or sudden deaths than the other in children or in adults under 65. The one direct comparison of outcomes found for this review enrolled Medicare patients with a mean age in the seventies, most of whom didn't have ADHD.²

Blood pressure and pulse rise by similar amounts with both classes

Mean increase in blood pressure versus placebo in randomized trials
Measure	Methylphenidate	Amphetamines
Adults, systolic	1.66 mm Hg (0.38 to 2.93); very low confidence	2.3 mm Hg (0.66 to 3.94); very low confidence
Adults, diastolic	1.60 mm Hg (0.29 to 2.91); very low confidence	1.91 mm Hg (0.17 to 3.65); lisdexamfetamine 3.07 mm Hg (0.69 to 5.45); both very low confidence
Children and adolescents, diastolic	2.42 mm Hg (1.69 to 3.15); low confidence	1.93 mm Hg (0.74 to 3.11); high confidence

Source: Farhat and colleagues, 2025, a network meta-analysis of randomized trials. Parentheses show 95% confidence intervals, followed by the CINeMA confidence rating.¹ Each column is a comparison with placebo. The two columns were not compared with each other here.

In adults the amphetamine figures are larger, and in children and adolescents methylphenidate has the larger diastolic figure. Methylphenidate was also at the top of the reported range for children's systolic pressure, 1.81 mm Hg (1.05 to 2.57; moderate confidence). The intervals overlap throughout.¹

For pulse in adults, the increases ranged from 4.37 beats per minute with methylphenidate (3.16 to 5.59; very low confidence) to 5.8 with viloxazine, a nonstimulant; the amphetamine estimate was 5.18 (3.47 to 6.89; very low confidence). When the analysis was restricted to licensed doses, only amphetamines or lisdexamfetamine were consistently associated with increased blood pressure against placebo in adults. Only four trials informed on the medium term and none on the long term.¹

The FDA labels don't separate the classes. The Adderall XR, Vyvanse and Concerta labels each describe a mean increase of about 2 to 4 mm Hg in blood pressure and 3 to 6 beats per minute in heart rate for CNS stimulants.^{3, 4, 5} Vyvanse is lisdexamfetamine, which the meta-analysis reported separately from other amphetamines.

A Cochrane review titled for amphetamines pooled methylphenidate trials

A 2025 Cochrane review, "Effect of amphetamines on blood pressure," found that heart rate increased by 3.71 beats per minute (95% CI, 3.27 to 4.14; 47 studies, 10,075 participants; high-certainty evidence), with similar effects in studies lasting at least eight weeks.⁶

That figure can't be set against a methylphenidate number. The review states that methylphenidate "is not chemically an amphetamine but has similar indications and effects," and included it. The included studies prescribed these drugs for ADHD, weight loss and other indications.⁶ Its result is an estimate for stimulants as a group.

The head-to-head outcome study was in older Medicare patients

Smith and colleagues compared 2,526 Medicare beneficiaries starting methylphenidate (1,340 people, mean age 76.7) or amphetamine (1,186 people, mean age 72.3). ADHD was recorded in 8.1% of the methylphenidate group and 16.3% of the amphetamine group.²

Starting methylphenidate was associated with a higher risk of the primary composite outcome, which counted heart attack, stroke or transient ischemic attack, ventricular arrhythmia, and death from any cause (hazard ratio 1.73; 95% CI, 1.36 to 2.19). The secondary analysis suggested the composite was driven by all-cause death (2.20; 1.62 to 3.00). Cardiovascular events alone did not differ significantly (1.14; 0.77 to 1.67).²

Only 18 of 261 deaths occurred within a month of a cardiovascular event, which the authors took to suggest that most deaths may not have been directly cardiovascular. They raised the possibility of residual confounding by indication or disease severity.²

In children and younger adults, the two classes haven't been separated

A pooled analysis of pediatric trials found statistically significant pre-to-post increases in systolic pressure, diastolic pressure and heart rate with amphetamines, and in systolic pressure only with methylphenidate. The amphetamine trials had 3,705 participants and the methylphenidate trials 1,171, and type of medication was not a significant moderator. Cardiovascular adverse effects of any kind were reported in 12.5% of participants in amphetamine studies and 12.7% in methylphenidate studies.⁷

For serious events, a large cohort of children and young adults found no evidence of increased risk with methylphenidate (hazard ratio 0.96; 95% CI, 0.31 to 2.97), and data were too sparse to model other individual drugs.⁸ In the companion cohort of adults aged 25 to 64, methylphenidate accounted for 45% of current use and amphetamine for 44%, and results were similar for specific medications.⁹

A small randomized crossover trial of 24-hour ambulatory blood pressure studied 13 children on methylphenidate (Ritalin or Concerta), amphetamine (Adderall or Adderall XR) or dextroamphetamine. It pooled the three against placebo and made no comparison among them.¹⁰

No study cited here compares Adderall with Vyvanse, immediate-release with extended-release forms, or the two classes at matched doses. In the Swedish long-term study, each medication was compared with no use, with no direct comparison between them;¹¹ I've covered those figures in the breakdown of that study. Outcome studies of heart attack and stroke are covered in a separate article.

Stimulants were not associated with larger increases in blood pressure or pulse than atomoxetine or viloxazine in the same meta-analysis.¹ Nonstimulants and guanfacine are covered in ADHD medication with high blood pressure or a heart condition.

Limitations of the evidence

This evidence has limitations. First, the blood pressure and pulse figures set two placebo comparisons side by side, from trials that used different dose ranges for each drug and lasted weeks. Second, the head-to-head outcome study enrolled older adults who mostly didn't have ADHD, and cause of death was unavailable. Nevertheless, the trial estimates, the pediatric adverse-effect rates and the FDA labels all describe effects of similar size for the two classes.

Because the class averages overlap, the choice between methylphenidate and an amphetamine rests on how well each controls symptoms and on the patient's own blood pressure and pulse, measured with the prescriber on each medication.

Frequently asked questions

Is Adderall or Ritalin harder on the heart?

The evidence doesn't establish that either is. In adult trials, systolic blood pressure rose by 1.66 mm Hg with methylphenidate and 2.3 mm Hg with amphetamines compared with placebo, with overlapping intervals and very low confidence in both estimates. No study reviewed here shows that either class is associated with more heart attacks, strokes or sudden deaths than the other in children or in adults under 65.¹

Does Vyvanse increase heart rate more than Adderall?

No study cited here compares Adderall with Vyvanse. Their FDA labels give the same average for stimulants: an increase of about 3 to 6 beats per minute in heart rate and about 2 to 4 mm Hg in blood pressure.^{3, 4}

Which ADHD medication is safest for the heart, methylphenidate or amphetamine?

Neither has been shown to be safer in the studies reviewed here. In children and adolescents, cardiovascular adverse effects of any kind were reported in 12.7% of participants in methylphenidate studies and 12.5% in amphetamine studies, and in a cohort of adults aged 25 to 64 results were similar for specific medications. The choice is made with the prescriber, based on symptom response and measured blood pressure and pulse.^{7, 9}

Does Concerta or Adderall raise blood pressure more?

In adult trials the increases against placebo were 1.66 mm Hg systolic with methylphenidate and 2.3 mm Hg with amphetamines. In children and adolescents the order reversed for diastolic pressure: 2.42 mm Hg with methylphenidate and 1.93 mm Hg with amphetamines. The drugs were each compared with placebo, and the intervals overlap.¹

Is methylphenidate riskier than amphetamine in older adults?

In 2,526 Medicare patients, starting methylphenidate was associated with a hazard ratio of 1.73 for a composite outcome that included death from any cause. Cardiovascular events alone did not differ significantly (1.14; 95% CI, 0.77 to 1.67), few patients had ADHD, and the authors raised the possibility of residual confounding.²

Chest pain, fainting, or shortness of breath during treatment needs immediate medical assessment. Call 911 or go to the nearest emergency department for severe symptoms. Medication changes are made with the prescriber.